Mirvetuximab soravtansine-gynx, a FRα-targeting antibody-drug conjugate, is effective in treating FRα-expressing platinum-resistant ovarian cancer. Bevacizumab, a vascular endothelial growth factor inhibitor, may potentiate antibody-drug conjugates through vascular normalization and improved intra-tumoral delivery. This study evaluated real-world outcomes of mirvetuximab with or without bevacizumab in platinum-resistant ovarian cancer.

METHODS:

We conducted a single-institution retrospective review of patients with platinum-resistant ovarian cancer treated with mirvetuximab between November 2022 and April 2025. Demographic, clinical, and survival data were abstracted from electronic medical records. Standard statistical analyses were performed using SPSS version 29.

RESULTS:

A total of 51 patients who initiated mirvetuximab were included in the analysis; 20 (39.2%) received combination mirvetuximab plus bevacizumab. Most patients (86.3%) had previous bevacizumab exposure. Patients received a median of 3 previous lines of therapy; 3 patients (5.9%) had platinum-refractory disease. The median FRα expression level was 75% (25% to 100%). Despite lower median FRα expression in the combination group than mirvetuximab alone (57.5% vs 80%, p<.001), combination therapy was associated with significantly improved median progression-free survival (8.5 vs 4.8 months, hazard ratio 0.34, 95% confidence interval 0.16 to 0.72, p=.003). No difference in overall survival was observed. The overall objective response was 37.3% (7.8% complete, 29.4% partial), consistent with previously published prospective data.

CONCLUSIONS:

In this real-world cohort, the addition of bevacizumab to mirvetuximab was associated with improved progression-free survival despite lower FRα expression, supporting potential synergy between these agents. Combination therapy may be considered for appropriately selected patients with FRα-expressing platinum-resistant ovarian cancer.

2026-05-01·Journal of Pathology Clinical Research

Reduced folate receptor alpha ( FOLR1 ) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab‐soravtansine therapy

Article

作者: Malte Gronewold ; Pia Hillmann ; Nora Schaumann ; Matthias Christgen ; Elna Kuehnle ; Martin Radner ; Henriette Christgen ; Jens Hachenberg ; Annika Nasdala ; Leonie D Kandt ; Christian Hartmann

Abstract:

Mirvetuximab‐soravtansine (MIRV‐S) is an antibody‐drug conjugate targeting folate receptor alpha (FOLR1). MIRV‐S is approved for the treatment of FOLR1‐positive, platinum‐resistant ovarian carcinoma. Patient eligibility is determined by immunohistochemistry (IHC) using a companion diagnostic (CDx) assay (FOLR1‐2.1, Ventana). This assay requires on‐slide positive controls (OPCs) to aid FOLR1 evaluation. The manufacturer recommends normal fallopian tube (NFT) tissue for OPCs. Estrogen receptor signaling represses FOLR1 in cell culture models. It is unknown whether hormonal factors, such as menopausal status, also impact on FOLR1 immunoreactivity in NFTs used as OPCs. To address this question, we studied FOLR1 protein expression in NFTs (n = 51) from women aged 26–83 years. IHC was performed with the FOLR1‐2.1 CDx assay. Immunoreactivity at apical and basolateral cell membranes was assessed using H‐scores (aH‐score and bH‐score respectively). Overall FOLR1 expression was evaluated using a combined H‐score (cH‐score; i.e. aH‐ and bH‐scores added together). Immunoreactivity scores in pre‐, peri‐, and postmenopausal age groups were compared with the chi‐square test for trends. NFTs showed variable FOLR1 protein expression [median aH‐score: 152.5, interquartile range (IQR): 120–175; median bH‐score: 35, IQR: 7–85; median cH‐score: 195, IQR: 140–245]. Apical immunoreactivity was age‐independent ( p = 0.619), but low or absent basolateral immunoreactivity (bH‐score <35) was associated with premenopausal age ( p = 0.018). Low overall FOLR1 expression (cH‐score <195) was also associated with premenopausal age ( p = 0.037). In conclusion, NFTs show an age‐dependent FOLR1 expression pattern, which likely reflects hormonal repression of FOLR1 in premenopausal women. NFT tissue from postmenopausal women is appropriate and meets the requirements for the current FOLR1 CDx assay.

2026-04-27·Chemical & biomedical imaging

Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer

Article

作者: Zhu, Hua ; Ma, Xiuli ; Liu, Yiqiang ; Guo, Xiaoyi ; Yang, Nan ; Liu, Jiayue ; Yang, Zhi ; Zhang, Yan

Triple-negative breast cancer (TNBC) is characterized by considerable heterogeneity and a poor response to chemotherapy. While folate receptor alpha (FRα) has attracted growing interest as a therapeutic target due to its frequent overexpression in numerous epithelial-derived tumors, we sought to visually evaluate its specific expression profile in TNBC. Therefore, we first evaluated FRα expression in 176 clinical TNBC specimens. The vast majority (84%) of samples showed no FRα expression, with the remainder showing low to moderate positivity (1+ to 3+), and no significant correlation was found with standard clinicopathological features. Given the low and variable FRα expression in TNBC, we developed an immunoPET probe, ⁸⁹Zr-DFO-Mirvetuximab, for noninvasive quantification. This probe was synthesized by conjugating the anti-FRα antibody Mirvetuximab with the chelator desferrioxamine (DFO), followed by ⁸⁹Zr-labeling, exhibiting high radiochemical purity (>95%) and exceptional stability. Cell uptake assays revealed time-dependent accumulation, which was blocked by excess Mirvetuximab, demonstrating FRα-specific targeting. Binding affinity measurement confirmed high affinity for FRα, with a dissociation constant (K _d) of 27.46 nM. We further validated the probe in vivo using micro-PET/CT imaging and biodistribution studies in mice bearing CAL51 (FRα-high) and MDA-MB-231 (FRα-low) tumors. The results demonstrated significantly higher uptake in CAL51 models compared to MDA-MB-231 models (17.17 ± 2.24%ID/g vs 3.79 ± 1.15%ID/g, P < 0.001), which was further confirmed by subsequent immunohistochemical analysis. In conclusion, ⁸⁹Zr-DFO-Mirvetuximab holds significant potential for noninvasively identifying TNBC patients with sufficient FRα expression for targeted therapies like Mirvetuximab soravtansine, thereby supporting improved patient stratification and treatment response monitoring.

项与 Mirvetuximab 相关的新闻（医药）

2026-06-25

·癌度

妇科肿瘤的"生物导弹":ADC药物如何改变卵巢癌、宫颈癌、子宫内膜癌的治疗，3款已获批、十几款在研,该怎么为自己争取机会！

卵巢癌、宫颈癌、子宫内膜癌,是威胁女性健康的三大妇科肿瘤。过去一旦化疗耐药,治疗的选择就变得非常有限。但这几年,一类被称为ADC(抗体药物偶联物)的"生物导弹"正在改变这个局面。它们像精确制导的导弹,把强效的化疗药精准送到癌细胞内部,在提高杀伤力的同时,减少对正常组织的伤害。目前已经有3款ADC获批用于妇科肿瘤,还有十几款在临床试验中展现出令人振奋的数据。今天癌度用尽量通俗的语言,帮你把这些新药梳理清楚。它们到底是怎么回事、对哪些患者有用、有哪些需要注意的副作用。本文参考文献刊例示意图一、ADC是什么,为什么对妇科肿瘤特别合适 ADC的全称是"抗体药物偶联物",通俗地说就是"生物导弹"。它由三部分组成:一个负责精准识别癌细胞的"抗体"(导航系统),一个强效的"化疗药弹头",以及把两者连接起来、在血液里保持稳定、进入癌细胞后才释放弹头的"连接子"。它最大的价值,是把传统化疗的"地毯式轰炸",变成了"精确打击"——正常细胞受到的伤害大大减少,而对癌细胞的杀伤更强、更集中。妇科肿瘤之所以特别适合ADC,是因为这类肿瘤细胞表面,往往大量表达一些在正常组织里很少见的"特异性靶点",这些靶点正好可以作为ADC的"导航目标"。目前已经发现的有效靶点包括FRα、HER2、组织因子、TROP2、B7-H4等。靶点是否表达、表达多少,直接决定了某一款ADC对你管不管用——这也是为什么用ADC前往往要先做靶点检测。二、已经获批、现在就能用的3款ADC 这是患者和家属最该关注的部分,因为它们是当下真实可及的选择。针对卵巢癌的——Mirvetuximab(MIRV)。它瞄准的靶点是叶酸受体α(FRα),适用于FRα阳性、铂耐药、既往接受过一到三线治疗的卵巢癌患者。在关键的Ⅲ期研究里,它相比化疗显著延长了控制疾病不进展的时间和总生存,死亡风险降低约三分之一,肿瘤明显缩小的比例(客观缓解率)也明显高于化疗。大约三到四成的复发性高级别浆液性卵巢癌患者是FRα阳性,适合用它。最需要注意的副作用是眼部症状(视物模糊等)和手脚麻木,用药期间需要定期看眼科。卵巢癌的ADC药物靶点和药物针对HER2阳性实体瘤的——T-DXd(德曲妥珠单抗)。它瞄准HER2,适用于HER2强阳性(免疫组化3+)的各种实体瘤,包括卵巢癌、子宫内膜癌、宫颈癌。在跨瘤种研究里,妇科肿瘤各亚组中,肿瘤明显缩小的比例可达四到六成,HER2越强阳性效果越好。它最需要警惕的副作用是间质性肺炎——发生率约一成多,虽然多数可控,但少数严重甚至可致命,所以用药期间必须定期做肺部CT,一旦出现干咳、气短要立刻就医。此外还有骨髓抑制等。针对宫颈癌的——Tisotumab vedotin(TV)。它瞄准组织因子,适用于复发或转移性宫颈癌的二线及以上治疗,而且不需要检测靶点,所有复发或转移的宫颈癌患者都可考虑。Ⅲ期研究显示它相比化疗延长了总生存、死亡风险降低约三成。它的副作用包括出血、眼部毒性(结膜炎、角膜炎,产品有眼部毒性的黑框警告,需定期看眼科)和手脚麻木。可以看到一个规律:这三款药各有各的靶点、各有各的适用人群,也各有各最该警惕的副作用(MIRV和TV盯眼睛、T-DXd盯肺),这也是为什么用药前后的针对性监测特别重要。子宫内膜癌的ADC药物靶点和药物三、正在路上、未来可期的新ADC 除了已获批的3款,还有一大批针对新靶点的ADC正在临床试验中,部分已经进入Ⅲ期,未来几年可能陆续走向临床。对目前标准治疗失败、在寻找机会的患者,这些是值得关注的方向(多数目前只能通过临床试验获得)。简单说几个最受关注的方向: TROP2这个靶点在超过九成的卵巢癌、子宫内膜癌、宫颈癌中都有表达,针对它的多款ADC已进入Ⅲ期; B7-H4在九成以上的子宫内膜癌和卵巢癌中表达,早期数据中肿瘤缓解的比例相当亮眼,也已启动Ⅲ期; 钙黏蛋白6在九成以上的高级别浆液性卵巢癌中表达,相关ADC的早期数据同样积极。此外还有针对Claudin 6、以及携带新型载荷的FRα新ADC等多个方向在推进。这些新药共同的特点是: 靶点覆盖面广(很多妇科肿瘤都表达)、早期数据令人振奋,但都还在验证阶段、尚未获批。它们最常见也最需警惕的副作用之一,仍是间质性肺炎(需肺部监测)。所以对它们,既要看到希望,也要明白它们目前主要是"临床试验里的机会",而不是已经成熟的常规选择。宫颈癌的ADC药物靶点和药物四、给患者和家属的实用建议第一,靶点检测是用ADC的前提。大部分ADC用之前要先查肿瘤组织里的靶点表达(比如FRα、HER2),查到对应靶点阳性才适合用对应的药(宫颈癌的TV是个例外,不需检测)。所以一个很实际的提醒:在确诊或复发时,尽量保留足够的肿瘤组织标本,以备后续做靶点检测,别等到要用药时才发现没标本可查。第二,ADC不是"没有副作用的神药",要重点盯几样。用MIRV、TV的要定期看眼科、用不含防腐剂的人工泪液(遵医嘱);用T-DXd以及部分在研ADC的,要定期做肺部CT,一出现干咳、气短立刻就医(警惕间质性肺炎);所有ADC都要定期查血常规(防骨髓抑制);出现手脚麻木要及时告诉医生。第三,临床试验是用上新药的重要途径。那些在研的新靶点ADC(TROP2、B7-H4等)大多还没上市,主要通过临床试验获得。如果标准治疗失败了,主动问问主治医生:有没有适合的ADC临床试验可以参加?(这正呼应我们常说的——别等无路可走才找试验。) 第四,靶点可能重叠,选哪个要个体化。不少卵巢癌患者的肿瘤会同时表达好几种靶点(FRα、HER2、TROP2、B7-H4等),也就是说可能同时符合好几款ADC的条件。具体先用哪个要结合既往治疗史、副作用耐受、药物可及性等综合判断,和医生商量。五、写在最后 ADC药物正在实实在在地改变妇科肿瘤的治疗格局。从卵巢癌的MIRV、宫颈癌的TV,到HER2阳性实体瘤的T-DXd,这三款已获批的药,已经让许多患者获益;而TROP2、B7-H4等新靶点的ADC正在临床试验中展现出令人期待的数据,未来几年会有更多选择。如果你或家人正面临妇科肿瘤的治疗决策,建议主动和医生讨论两个问题:做过相关的靶点检测吗?有没有适合的ADC药物或临床试验可以参加? 每一次主动的咨询,都是在为自己争取更多的可能。如果您有靶点检测报告需要解读、或想了解是否适合ADC临床试验,点击左下角“阅读原文”，或关注公众号后点菜单栏“联系我们”，了解诊疗最新进展！直接在微信长按下图扫描二维码添加癌度王博企业微信！ (本文为科普解读,不构成医疗建议。具体用药请与主治医生充分沟通。文中数据来源于已发表的临床研究,部分在研药物尚未获批,需通过临床试验途径获取。) 参考文献： Kathleen N. Moore，et al., Antibody–drug conjugates in gynaecological cancers: opportunities and challenges, Nature Reviews Clinical Oncology (2026) 往期推荐能"看见"看不见的残留癌细胞，比CT提前一年发现复发——MRD 这项“最准”的检测技术，为什么还不能改变治疗结局! 每年515万例新发癌症，占全球四分之一——五十年前胃癌食管癌最多，现在肺癌肠癌乳腺癌居首，中国癌症谱已彻底改头换面! 两个新药“组队”打肿瘤！TROP-2 ADC联手PD-1/VEGF双抗，晚期乳腺癌、肺癌后线治疗新探索! HER2阳性肠癌脑转移无药可用？TL938突破血脑屏障，联合方案颅内控制率100%！点赞收藏分享点亮小手爱心，送来温暖鼓励

2026-06-11

·Biotech前瞻

ASCO 26会后复盘：七大瘤种重要研究，正在重塑创新药竞争逻辑

点击蓝字关注我们本期看点引言 2026 ASCO已经结束。相比单点追逐某一个药物的ORR、PFS或OS，今年更值得关注的是各大瘤种背后共同呈现出的研发趋势：治疗不断前移，精准分层继续细化，ADC、双抗、细胞治疗和ctDNA/MRD正在从探索性工具变成影响临床路径的重要变量。本文梳理的重点研究（LBA、RO、O）覆盖肺癌、乳腺癌、消化道肿瘤、妇科肿瘤、头颈肿瘤、泌尿肿瘤和泛实体瘤等多个板块。 01 肺癌：32项研究，仍是创新药竞争最密集的主战场肺癌领域主要研究汇总如下：肺癌板块的核心变化，是治疗线数和治疗阶段都在继续前移。RET、EGFR、ALK等驱动基因研究不再局限于晚期后线，而是进入辅助、新辅助、一线和脑转移管理场景。与此同时，HARMONi-6、OptiTROP-Lung05、ROSETTA Lung-02等研究说明，PD-1/VEGF双抗、TROP2 ADC和PD-L1 ADC正在向传统PD-1联合化疗的主战场发起挑战。这也意味着，肺癌创新药的竞争逻辑已经发生变化。过去，一个药物只要在后线取得较高ORR，就有较强商业想象力；现在更重要的是能否进入一线、围术期或明确分子分层人群，并在PFS、OS、颅内控制和长期安全性上形成系统优势。 02 乳腺癌：31项研究，ADC前移与内分泌精准化并行乳腺癌领域主要研究汇总如下：乳腺癌板块最清晰的主线，是ADC继续前移，尤其是在三阴性乳腺癌中。一线mTNBC已经不再只是化疗联合免疫的竞争，sacituzumab govitecan、Dato-DXd、iza-bren等ADC正在进入更早治疗阶段。另一个重要变化来自ER+/HER2-乳腺癌。SERD、CDK4/6抑制剂、ESR1突变动态监测和基因表达风险分层正在共同影响治疗排序。早期乳腺癌则呈现另一种趋势：一方面高危人群需要治疗强化，另一方面外科、腋窝处理、随访模式也在持续降阶。乳腺癌已经从单纯“新药竞争”进入“药物、检测和治疗路径共同优化”的阶段。 03 消化道肿瘤：40项研究，胰腺癌RAS、CRC ctDNA和肝癌局部联合最值得关注消化道肿瘤领域主要研究汇总如下：消化道肿瘤是今年ASCO最值得深读的板块之一。胰腺癌中，daraxonrasib三期研究是最具行业信号意义的研究之一，因为它指向了RAS靶向在胰腺癌中的真实突破可能。结直肠癌方面，ctDNA相关研究密集出现，说明辅助治疗决策正在从传统病理分期走向分子残留病灶指导。肝癌则体现了另一条路径：局部治疗与系统治疗进一步融合。EMERALD-3、卡瑞利珠单抗联合阿帕替尼和TACE等研究，说明中期或栓塞适用HCC正在从单纯TACE时代，进入免疫、抗血管生成和局部治疗整合阶段。对于BD而言，消化道肿瘤的机会不再只是“难治瘤种高未满足需求”，而是已经出现了多个可分层、可注册、可前移的方向。 04 妇科肿瘤：17项研究，子宫内膜癌验证长期生存，卵巢癌继续寻找OS突破妇科肿瘤主要研究汇总如下：妇瘤板块今年的重点不是单纯新药数量，而是疗效终点和治疗路径更加清晰。子宫内膜癌中，RUBY和NRG-GY018相关研究继续巩固免疫联合化疗的一线地位，尤其在dMMR/MSI-H人群中，长期生存和潜在治愈模型成为讨论重点。卵巢癌则仍然围绕铂耐药和复发人群寻找突破。ROSELLA、CHIPRO、mirvetuximab、TUB040、ABBV-400、AZD8205等研究显示，卵巢癌正在成为ADC和新免疫机制的重要验证场景。与肺癌、乳腺癌不同，卵巢癌的行业价值更依赖OS、耐药后治疗和明确靶点表达分层，而不是单纯早期ORR。 05 头颈肿瘤：23项研究，治疗降阶、低成本免疫和新靶点共同推进头颈肿瘤主要研究汇总如下：头颈肿瘤板块不像肺癌和乳腺癌那样形成单一热门靶点，但今年研究非常有现实意义。一方面，HPV阳性口咽癌、鼻咽癌和口腔癌都在探索治疗强度优化；另一方面，复发/转移性头颈鳞癌正在通过超低剂量免疫、节拍化疗、EGFR/MET双靶点、PD-1/VEGF双抗和新型ADC寻找新机会。这一板块对产业的启示是：头颈癌的创新不一定只来自高价新药，也来自治疗路径重构、毒性管理和资源可及性优化。对于中国企业而言，鼻咽癌、头颈鳞癌和部分罕见头颈肿瘤，仍有较强本土开发和全球差异化潜力。 06 泌尿肿瘤：31项研究，前列腺癌围术期强化，尿路上皮癌ADC持续前移泌尿肿瘤主要研究汇总如下：泌尿肿瘤今年最重要的变化，是系统治疗继续向早期阶段推进。PROTEUS代表了高危局限或局部晚期前列腺癌围术期强化治疗的方向；TALAPRO-3、ZZFIRST、FUZUPRO等研究则说明PARP抑制剂与AR通路抑制剂的组合仍在向更早疾病阶段移动。尿路上皮癌方面，Nectin-4 ADC已经从晚期治疗延伸到围术期MIBC和一线联合。EV-302长期随访进一步强化EV+pembrolizumab的地位，而LY4052031、LY4101174、BT8009、9MW2821等新ADC也说明该靶点已经进入多资产拥挤竞争阶段。未来泌尿肿瘤的核心问题，不再只是药物有效性，而是如何在前移场景中平衡疗效、毒性、生活质量和患者筛选。 07 泛实体瘤：13项研究，细胞治疗和新型免疫调节剂仍在寻找清晰人群泛实体瘤主要研究汇总如下：泛实体瘤板块仍以早期探索为主，但代表了下一代免疫治疗的重要方向。TIL、TCR-T、TCER、PVR抗体、LILRB/KIR抑制剂、CD80-Fc-IL2变体等研究说明，实体瘤免疫治疗正在从单纯PD-1时代走向更复杂的免疫微环境重塑阶段。不过，这一板块也最需要冷静。多数研究还处于早期，真正的产业价值不在于“概念新”，而在于能否找到明确抗原、明确人群、明确疗效终点和可规模化生产路径。实体瘤细胞治疗和新型免疫调节剂未来仍有想象力，但从ASCO数据走向注册和商业化，还需要更长验证周期。 03 总结与展望：2026 ASCO的真正信号，是创新药评价标准变严了把各个瘤种放在一起看，2026 ASCO最重要的不是某一个靶点短期热度，而是创新药评价标准正在系统升级。第一，治疗前移已经成为放大资产价值的主要路径。肺癌、乳腺癌、前列腺癌、膀胱癌、胃癌和肝癌都在向辅助、新辅助、围术期或一线推进。后线ORR可以证明药物有活性，但真正决定商业天花板的是能否进入更早治疗阶段。第二，OS、EFS、MFS、MRD和ctDNA等终点权重继续上升。资本市场和BD部门已经不再满足于早期缓解率，而是更关注长期获益、复发风险降低和治疗路径改变。第三，ADC和双抗已经进入标准治疗竞争期。它们不再只是后线补充，而是在肺癌、乳腺癌、妇瘤、尿路上皮癌和头颈癌中不断向前线推进。下一阶段竞争的重点，是疗效、安全性、联合潜力和人群筛选的综合平衡。第四，中国创新药在ASCO中的存在感继续提升，但全球化门槛也更高。依沃西单抗、sac-TMT、舒沃替尼、SHR-A2102、多个国产ADC和双抗资产均出现在关键研究中，但未来能否获得高质量BD，不只取决于早期数据是否亮眼，更取决于全球多中心验证、OS证据、注册路径和商业化确定性。因此，2026 ASCO之后，真正值得持续跟踪的资产，要同时满足三个条件：进入前线、定义人群、证明长期获益。这也是未来创新药BD、投资和临床开发最核心的判断标准。 ★

ASCO会议抗体药物偶联物临床3期临床结果

2026-06-04

·EINPresswire

NHS rolls out life-extending drug for hundreds of women with ovarian cancer

Hundreds of women with hard-to-treat ovarian cancer could benefit from a new, life-extending drug on the NHS from today – the first new addition to NHS treatment in over 20 years. The new targeted therapy – mirvetuximab soravtansine – will be offered to patients living with ovarian cancer whose disease has stopped responding to standard (platinum-based) chemotherapy, providing new hope of extra time to live. The drug combines a ‘homing’ antibody with a cancer-killing medicine – often described by scientists as a ‘biological missile’ or ‘trojan horse’ therapy. It works by attaching to ovarian cancer cells that have a protein called folate receptor alpha (FRα) on their surface, before releasing a cancer-killing molecule which destroys the cell from within. In a major global clinical trial involving eight NHS hospitals. the treatment delayed cancer progression and prolonged survival, with patients living 16.5 months on average compared to 12.8 months with chemotherapy. One patient said the treatment helped “add life to years”, enabling her to get on with life “rather than spending it in bed recovering from the side effects of chemotherapy”. Following a recommendation by the National Institute for Health and Care Excellence (NICE) today, the treatment will be available for patients with epithelial ovarian, peritoneal or fallopian tube cancer that has become resistant to platinum-based chemotherapy and whose tumours contain the FRα protein the drug targets. The treatment is given intravenously (via a drip) over 2-4 hours, once every three weeks. The drug may also have more tolerable side effects than traditional chemotherapy – with the treatment aimed more precisely at cancer cells than chemotherapy, which harms healthy cells The NHS estimates up to 400 patients in England each year could benefit. Patricia Hill, 64, a retired NHS physiotherapist from North London who also spent six years working in cancer care, was diagnosed with ovarian cancer in 2023 and began treatment with mirvetuximab soravtansine in January this year. She said : “It’s been incredibly positive. Previously, I’ve had three different lines of chemotherapy, and this is the first time that I’ve actually been able to get on with my life in terms of the impact of side effects.” “The feelings of isolation and loneliness that you have undergoing conventional chemotherapy are totally or more or less totally eradicated when using mirvetuximab. It actually adds life to years, rather than spending your life in bed recovering from the side effects of chemotherapy.” Since starting treatment, Patricia has been to the theatre and cinema, dined out with friends, and in March flew to Ireland for a family reunion – which she said she could not have done on standard chemotherapy. She also was able to attend the Chelsea Flower Show. The treatment will be available from today, with NHS England fast-tracking access for patients through its Cancer Drugs Fund, which has provided early access to innovative new treatments to more than 100,000 patients in the past 10 years. Professor Ruth Plummer, NHS national clinical lead for cancer drugs, said : “This represents the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades – and we’re delighted it will now offer hundreds of women much-needed hope of precious extra time with their loved ones. “It is part of a growing wave of more targeted cancer therapies which, by homing in on specific features of cancer cells, are helping us improve patients’ lives.” Ovarian cancer is one of the leading causes of death from gynaecological cancer worldwide. In the UK, there are around 7,500 new diagnoses each year. Standard treatment for ovarian cancer typically involves surgery and chemotherapy, but around 80% of patients with advanced disease relapse and most eventually develop resistance to chemotherapy. More than a third of patients (37%) also saw their tumours shrink by at least 30%, compared to 16% with chemotherapy in trials. Jenny Green, 71, a Royal Mail worker from Bishop’s Stortford, Hertfordshire , has been living with ovarian cancer since her diagnosis in 2017 and received mirvetuximab soravtansine through the clinical trial. She said : “I seem to have tolerated it very well, with hardly any side effects at all. That’s been amazing! I had a scan that showed my cancer nodules were shrinking, and my bloods were coming back into range – which is all pretty good to hear!” Minister for Public Health, Sharon Hodgson said : “This is an important moment for hundreds of women with ovarian cancer and a testament to our commitment to getting the most promising treatments to NHS patients as quickly as possible. “Critically, today’s decision means that patients will have a better quality of life than they otherwise would.” Victoria Clare, Chief Executive Officer at Ovacome, the UK’s ovarian cancer support charity, said : “This is really positive news for many with ovarian cancer. For those whose cancers are platinum resistant, this offers hope and a chance of a new treatment on the NHS.” “This decision has the potential to make a real difference to those who are able to access this treatment. We are delighted that NICE has listened to patients, their families and the clinicians.” Mirvetuximab soravtansine (Elahere) has been developed by AbbVie. It represents the first new addition to NHS treatment for this group of patients since the rollout of liposomal doxorubicin and paclitaxel in the early 2000s. Common side effects of the treatment include eye problems (such as blurred vision or dry eyes), tiredness, nausea, and low blood counts, with most effects manageable with monitoring and supportive care. Kelly Sanderson Schrems, Vice President and General Manager, AbbVie UK said : “Today’s decision is an important moment for the ovarian cancer community, who have waited more than two decades for a new treatment to be NICE recommended for this advanced stage of the disease. “AbbVie is committed to investing in areas of high unmet need and bringing innovative medicines to patients. We support efforts to create a system that recognises the value these medicines bring which is essential not only for UK patients but for the UK ecosystem more broadly.” For background Patients eligible for this treatment will be referred to one of the hospitals that provide systematic anti-cancer therapy for gynaecological cancers. Clinical trials for Mirvetuximab have taken place at the following hospitals in the UK: St Bartholomew’s Hospital-Barts Health NHS Trust University College London Hospital The Royal Marsden NHS Foundation Trust The Christie NHS Foundation Trust Peterborough City Hospital Royal Devon and Exeter Hospital (Wonford) University Hospitals Coventry and Warwickshire Beatson West of Scotland Cancer Centre, Glasgow Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准临床结果临床3期

100 项与 Mirvetuximab 相关的药物交易

登录后查看更多信息